Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Article Details
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
Authors (44)
Luciano J. Costa
Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham
Nizar J. Bahlis
Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
Aurore Perrot
Ajay K. Nooka
Emory University, Winship Cancer Institute, Atlanta
Jin Lu
Center for Biological Physics, Arizona State University
Charlotte Pawlyn
Roberto Mina
Division of Hematology, Department of Molecular Biotechnology and Health Sciences, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
Gaston Caeiro
Hospital Privado Universitario de Córdoba Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina
Alain Kentos
Department of Hematology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium
Vania Hungria
Clinica São Germano, São Paulo
Donna Reece
Princess Margaret Cancer Centre, Toronto
Ting Niu
Department of Hematology, West China Hospital, Sichuan University, Chengdu
Anne K. Mylin
Department of Hematology, Rigshospitalet, Copenhagen
Charlotte T. Hansen
Department of Hematology, Odense University Hospital, Odense, Denmark
Raphael Teipel
Department of Internal Medicine I, University Hospital Dresden, Technical University Dresden, Dresden, Germany
Britta Besemer
Department of Internal Medicine II, University Tübingen, Tübingen, Germany
Meletios A. Dimopoulos
Elena Zamagni
Satoshi Yoshihara
Kihyun Kim
Division of Hematology–Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
Chang Ki Min
Department of Hematology, College of Medicine, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul, South Korea
Paul Geerts
Department of Internal Medicine, Isala Klinieken, Zwolle, the Netherlands
Elena Van Leeuwen-Segarceanu
Department of Hematology, St. Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands
Agata Tyczyńska
Medical University of Gdańsk, Department of Hematology and Transplantology and University Clinical Center Gdańsk, Department of Hematology, Transplantology and Cellular Therapies, Gdańsk, Poland
Juan Luis Reguera
Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de la Universidad de Sevilla, Seville, Spain
Magnus Johansson
Department of Cell & Molecular Biology, Uppsala University
Markus Hansson
Sahlgrenska University Hospital, Gothenburg, Sweden
Mehmet Turgut
Ondokuz Mayıs University, Samsun, Turkey
Mark Grey
Lancashire Haematology Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool Victoria Hospital, Blackpool, United Kingdom
Surbhi Sidana
Stanford University School of Medicine, Palo Alto, CA
Paula Rodriguez-Otero
Joaquín Martínez-López
Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Complutense University of Madrid, Centro Nacional de Investigaciones Oncológicas, Madrid Institute of Cancer, Madrid
Hamza Hashmi
Memorial Sloan Kettering Cancer Center, New York
Robin Carson
Johnson & Johnson, Spring House, PA
Rachel Kobos
Johnson & Johnson, Raritan, NJ
Weili Sun
Johnson & Johnson, Los Angeles
Kristen Lantz
Johnson & Johnson, Spring House, PA
Anne Seifert
Johnson & Johnson, High Wycombe, United Kingdom
Deborah Briseno-Toomey
Johnson & Johnson, Yorba Linda, CA
Lisa O’Rourke
Johnson & Johnson, Spring House, PA
Maria Rubin
Johnson & Johnson, Raritan, NJ
Diego Vieyra
Johnson & Johnson, Spring House, PA
Lijuan Kang
Johnson & Johnson, Los Angeles
Maria Victoria Mateos
Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca–Consejo Superior de Investigaciones Científicas), Centro de Investigación Biomédica en Red de Cáncer, Salamanca, Spain